Clinical Trial Update: Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005) [Phase 2]

View source ↗

Summary

A phase 2 trial evaluated the efficacy and tolerability of MK0533 in patients with Type 2 diabetes mellitus. The trial was terminated early.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• MK0533

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Diabetes Mellitus Type 2 | Phase 2 | Status: TERMINATED